$0.64
-0.00 (-0.48%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BBLG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluation of NB1 Bone Graft Following Lumbar Interbody ArthrodesisNCT03810573FusionRandomized · Double-masked · Treatment | Not applicable | Unknown status | Device: NB1 | Degenerative Disc Disease, Spondylolisthesis | 30 | 2025-06-01 | 2024-03-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19